Avadel Pharmaceuticals (Avadel Pharmaceuticals) Debt-to-Equity : 0.03 (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Avadel Pharmaceuticals Debt-to-Equity?

Avadel Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.93 Mil. Avadel Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.69 Mil. Avadel Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $87.74 Mil. Avadel Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Avadel Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

AVDL' s Debt-to-Equity Range Over the Past 10 Years
Min: -6.2 Med: 0.02 Max: 41.67
Current: 0.03

During the past 13 years, the highest Debt-to-Equity Ratio of Avadel Pharmaceuticals was 41.67. The lowest was -6.20. And the median was 0.02.

AVDL's Debt-to-Equity is ranked better than
88.79% of 856 companies
in the Drug Manufacturers industry
Industry Median: 0.285 vs AVDL: 0.03

Avadel Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Avadel Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avadel Pharmaceuticals Debt-to-Equity Chart

Avadel Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-4.27

0.80

1.85

-6.20

0.03

Avadel Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-6.20	-3.02	0.16	0.22	0.03

Competitive Comparison of Avadel Pharmaceuticals's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Avadel Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avadel Pharmaceuticals's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avadel Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Avadel Pharmaceuticals's Debt-to-Equity falls into.

Avadel Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Avadel Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.934	+	1.69)	/	87.739
	=	0.03

Avadel Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.934	+	1.69)	/	87.739
	=	0.03

Avadel Pharmaceuticals (NAS:AVDL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Avadel Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Avadel Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Avadel Pharmaceuticals (Avadel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avadel Pharmaceuticals PLC (NAS:AVDL) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

AWK1:Germany AWK1:Germany

Address

10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380

Website

https://www.avadel.com

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.

Executives

Thomas S Mchugh	officer: Chief Financial Officer	2280 SCHUETZ ROAD, ST. LOUIS MO 63146
Mark Anthony Mccamish	director	C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025
Geoffrey Michael Glass	director	4721 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Greg J Divis	director, officer: Chief Executive Officer	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Richard J Kim	officer: Chief Commercial Officer	16 FAIRWAY DRIVE, WEST WINDSOR NJ 08550
Eric J Ende	director	C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Linda Palczuk	director	7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD 21046
Peter Thornton	director	TECHNOPATH LIFE SCIENCES PARK, FORT HENRY, BALLINA, CO. TIPPERARY L2 V94 FF1P
Douglas J Williamson	officer: Chief Medical Officer	AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN L2 D02 T390
Sandra L Hatten	officer: See Remarks	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Jason Vaughn	officer: Sr. VP, Technical Operations	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Jordan Dubow	officer: Chief Medical Officer	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Michael F Kanan	officer: See Remarks	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
David P Gusky	officer: See Remarks	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Michael S Anderson	director, officer: Chief Executive Officer	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15